Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus gemcitabine in metastatic castration-resistant prostate cancer
ChiCTR2500101620Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab and gemcitabine in prostate cancer (PCa), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Overall survival and Radiographic progression-free survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
toripalimabgemcitabine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2500101620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101620.